BLTE - NASDAQ
Belite Bio, Inc
$144.46
+6.4%Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
At a Glance
Live Snapshotblte
Cash and Short Term Investments
Last Annual Value
492.42M
3-Year CAGR
127%
5-Year CAGR
81%
10-Year CAGR
34%
Belite Bio, Inc Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Belite Bio, Inc NASDAQ:BLTE | 492.42M | 77.4% | 95.3% | N/A | |
 ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 819.69M | 23.2% | 9.5% | 4.5% | |
 ADMA Biologics, Inc. NASDAQ:ADMA | 87.63M | 19.5% | 11.4% | 19.1% | |
 Praxis Precision Medicines, Inc. NASDAQ:PRAX | 599.33M | 94.6% | 16.8% | N/A | |
 Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 383.33M | 10.2% | 19.6% | N/A | |
 Ligand Pharmaceuticals Incorporated NASDAQ:LGND | 733.52M | 62.7% | 16.5% | 17.9% | |
 Viking Therapeutics, Inc. NASDAQ:VKTX | 705.74M | 24.9% | 28.4% | 48.9% | |
 Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX | 1.03B | 22.5% | 25.2% | 55.9% | |
 Arcutis Biotherapeutics, Inc. NASDAQ:ARQT | 220.98M | -6.7% | -10.7% | N/A | |
 Dyne Therapeutics, Inc. NASDAQ:DYN | 1.11B | 108.2% | 24.1% | -5.3% | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 305.47M | 21.7% | 70.3% | 60.3% |
Belite Bio, Inc Fair Value Envelope
Related Guides
Continue your BLTE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.